ABOUT AVIDITY

Our mission is to profoundly improve people’s lives by delivering a new class of RNA therapeutics – AOCs. Our proprietary AOCs are designed to combine the specificity of monoclonal antibodies with the precision of oligonucleotide therapies to target the root cause of diseases previously untreatable with RNA therapeutics. Our advancing and expanding pipeline includes multiple skeletal muscle programs. We are also broadening the reach of AOCs beyond muscle tissues through both internal discovery efforts and key partnerships as the company continues to deliver on the RNA revolution.

Committee Composition

Avidity Biosciences has the committees listed below in place. The grid below provides an overview of the individuals that make up each committee. To learn more about a particular committee or an individual member click the titles below.

	Audit Committee	Human Capital Management Committee	Nominating and Corporate Governance Committee
Carsten Boess	Chair
Sarah Boyce
Noreen Henig, M.D.	Member		Chair
Edward Kaye, M.D.		Chair	Member
Jean Kim	Member
Arthur A. Levin
Simona Skerjanec
Tamar Thompson		Member	Member
Troy Wilson, PhD, JD		Member

Chair
Member